Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Triple combination superior to double combination.

B Grodeck

    Positively Aware : the Monthly Journal of the Test Positive Aware Network
    |January 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    3TC receives full approval.

    Positively aware : the monthly journal of the Test Positive Aware Network·1997
    Same author

    Nelfinavir (Viracept) moves up the ranks.

    Positively aware : the monthly journal of the Test Positive Aware Network·1997
    Same author

    Marijuana as medicine?

    Positively aware : the monthly journal of the Test Positive Aware Network·1997
    Same author

    Is immune boosting the next step?

    Positively aware : the monthly journal of the Test Positive Aware Network·1997
    Same author

    The kissing question and other ICAAC highlights.

    Positively aware : the monthly journal of the Test Positive Aware Network·1996
    Same author

    A, B, C, D, E...any school child can tell you not to mess with viral hepatitis.

    Positively aware : the monthly journal of the Test Positive Aware Network·1995

    Triple combination therapy including nevirapine (an investigational nonnucleoside reverse transcriptase inhibitor) showed improved surrogate markers like increased T-cells and decreased viral load compared to dual therapy in HIV patients.

    Area of Science:

    • HIV/AIDS Research
    • Antiretroviral Therapy
    • Immunology

    Background:

    • Antiretroviral therapy is crucial for managing HIV infection.
    • Evaluating novel drug combinations is essential for improving treatment outcomes.
    • Nevirapine is an investigational nonnucleoside reverse transcriptase inhibitor.

    Purpose of the Study:

    • To compare the efficacy of a triple combination therapy (AZT, ddI, nevirapine) versus a double combination therapy (AZT, ddI) in HIV patients.
    • To assess the impact of these regimens on surrogate markers such as T-cell counts and viral load.
    • To explore potential differences in clinical endpoints between the treatment groups.

    Main Methods:

    • A study involving 241 patients within the AIDS Clinical Trials Group (ACTG).

    Related Experiment Videos

  • Comparison of treatment outcomes between patients receiving triple therapy (AZT, ddI, nevirapine) and double therapy (AZT, ddI).
  • Monitoring of surrogate markers including T-cell counts and viral load over a 40-week period.

    • Main Results:

    • The triple combination therapy demonstrated a 40% increase in T-cells over baseline, sustained for 40 weeks.
    • Greater reductions in viral load were observed in the triple combination group.
    • No significant difference in clinical endpoints was noted, except for a trend towards fewer events in the triple combination group, particularly in patients with low baseline T-cell counts (<50).

    Conclusions:

    • Triple combination therapy with AZT, ddI, and nevirapine shows superior surrogate marker response compared to dual therapy.
    • Nevirapine-containing regimens may offer benefits in managing HIV, particularly in specific patient subgroups.
    • Further research into clinical endpoints is warranted for nevirapine-based treatment strategies.